Screener / SEC EDGAR /CIK 0000313143 /10-K filed May 20, 2026, compared with May 21, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Haemonetics Corp HAE

Compare with peers Embed
FY2026 at a glance

Sales down 2.0%, free cash flow up to $260.4M

XBRL, from each 10-K
RevenueStatements
$1.3B from $1.4B in FY2025
FY2017FY2026
Net incomeStatements
$97.3M from $167.7M in FY2025
FY2017FY2026
Free cash flowStatements
$260.4M from $142.4M in FY2025
FY2017FY2026
EPS (diluted)Statements
$2.05 from $3.31 in FY2025
FY2017FY2026
Operating marginStatements
11.7% from 16.3% in FY2025
FY2017FY2026
Total debtStatements
$1.2B from $1.2B in FY2025
FY2017FY2026

The latest figures

Price and key numbers

From EDGAR
All key numbers (43)
EPS (ttm)
2.26
Sales (ttm)
1.4B
Net income (ttm)
103.9M
Sales growth
-2.0%
EPS growth
-38.1%
Sales Q/Q
+9.3%
Free cash flow
298.2M
Gross margin
59.6%
Oper. margin
12.8%
Net margin
7.5%
FCF margin
21.6%
ROA
4.3%
R&D / sales
4.5%
Dividend
-
Debt/Eq
1.27
Curr. ratio
2.84
Cash
260.7M
Op. cash flow (ttm)
344.9M
EBITDA
268.5M
EBITDA margin
20.1%
Net debt
875.9M
Quick ratio
1.83
Interest cover
8.12
ROIC
5.9%
FCF after stock pay
226.6M
Debt / FCF (years)
4.36
Goodwill / assets
27.4%
Oper. margin low 5y
8.1%
Tax rate
24.0%
Stock pay / sales
2.5%
Shares out.
45.5M
Shares Y/Y
-6.7%
Book / share
19.73
Cash / share
5.73
Sales / share
30.36
Asset turnover
0.57
Inventory turns
1.78
Days sales out.
59
Sales 3Y CAGR
+4.5%
Sales 5Y CAGR
+8.9%
EPS 3Y CAGR
-2.9%
EPS 5Y CAGR
+5.8%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2017 to FY2026

Each fiscal year from its own 10-K · XBRL

Revenue 1.3B +4.7% a year Net income 97.3M
FY2017 revenue 886.1M · RevenueFromContractWithCustomerIncludingAssessedTax, 0000313143-19-000022 FY2017 net income -26.3M · NetIncomeLoss, 0000313143-19-000022 886.1M FY2017 FY2018 revenue 903.9M · RevenueFromContractWithCustomerIncludingAssessedTax, 0000313143-20-000028 FY2018 net income 45.6M · NetIncomeLoss, 0000313143-20-000028 903.9M FY2018 FY2019 revenue 967.6M · RevenueFromContractWithCustomerIncludingAssessedTax, 0000313143-21-000023 FY2019 net income 55.0M · NetIncomeLoss, 0000313143-21-000023 967.6M FY2019 FY2020 revenue 988.5M · RevenueFromContractWithCustomerIncludingAssessedTax, 0000313143-22-000024 FY2020 net income 76.5M · NetIncomeLoss, 0000313143-22-000024 988.5M FY2020 FY2021 revenue 870.5M · RevenueFromContractWithCustomerIncludingAssessedTax, 0000313143-23-000014 FY2021 net income 79.5M · NetIncomeLoss, 0000313143-23-000014 870.5M FY2021 FY2022 revenue 993.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000313143-24-000020 FY2022 net income 43.4M · NetIncomeLoss, 0000313143-24-000020 993.2M FY2022 FY2023 revenue 1.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000313143-25-000025 FY2023 net income 115.4M · NetIncomeLoss, 0000313143-25-000025 1.2B FY2023 FY2024 revenue 1.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000313143-26-000050 FY2024 net income 117.6M · NetIncomeLoss, 0000313143-26-000050 1.3B FY2024 FY2025 revenue 1.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000313143-26-000050 FY2025 net income 167.7M · NetIncomeLoss, 0000313143-26-000050 1.4B FY2025 FY2026 revenue 1.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000313143-26-000050 FY2026 net income 97.3M · NetIncomeLoss, 0000313143-26-000050 1.3B FY2026

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2017 to FY2026 (9 years).

From the same starting line, FY2017 to FY2026

Revenue, net income and free cash flow, each set to 100 in FY2017. What happened, from the 10-Ks. Not a forecast.

FY2017 = 100
100 200 300 Revenue: $886.1M in FY2017, $1.3B in FY2026 REVENUE $1.3B · 1.5x Free cash flow: $83.6M in FY2017, $260.4M in FY2026 FREE CASH FLOW $260.4M · 3.1x FY2017 = 100FY2022FY2026
Revenue 1.5x $886.1M to $1.3B
Free cash flow 3.1x $83.6M to $260.4M

Growth per share, FY2016 to FY2026

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +11.6% a year FY2018 $0.85 to FY2026 $2.05, 8 years
Book value per share +1.7% a year FY2016 $14.17 to FY2026 $16.82, 10 years
Free cash flow per share +30.6% a year FY2016 $0.38 to FY2026 $5.50, 10 years
500 1000 1500 100 Book value / share: $14.17 in FY2016, $16.82 in FY2026 BOOK VALUE / SHARE $16.82 · 1.2x FCF / share: $0.38 in FY2016, $5.50 in FY2026 FCF / SHARE $5.50 · 14.4x FY2016 = 100FY2021FY2026

Each line is set to 100 in FY2016, so a line at 200 has doubled. What was filed, not a forecast. A line is left out when it is not above zero in every year.

Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Mar 28, 2026 $2.05$16.82$5.50
Mar 29, 2025 $3.31$16.18$2.81
Mar 30, 2024 $2.29$18.68$2.79
Apr 1, 2023 $2.24$15.91$1.59
Apr 2, 2022 $0.84$14.59$1.48
Apr 3, 2021 $1.55$14.26$1.40
Mar 28, 2020 $1.48$11.33$2.11
Mar 30, 2019 $1.04$12.62$0.76
Mar 31, 2018 $0.85$14.06$2.72
Apr 1, 2017 -$0.51$14.35$1.62
Apr 2, 2016 -$1.09$14.17$0.38

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2026 · 10-K XBRL, no share price used

Net current asset value, FY2026, in dollars
  • + Current assets $834.9M
  • − All liabilities (total assets less equity) $1.6B
  • = Net current asset value -$764.7M
Per share, year by year
Tangible book value, FY2026, in dollars
  • + Shareholders' equity $796.3M
  • − Goodwill $656.4M
  • − Other intangible assets $447.7M
  • = Tangible book value -$307.7M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result. This company does not tag total liabilities, so total assets less equity is used (it includes any non-controlling interest).

HAE against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
-2.0%142nd of 155 · median +10.5%
Net margin
-4.1%15.3%
7.5%73rd of 154 · median 6.8%
Return on equity
-5.2%18.5%
11.6%62nd of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
21.6%28th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
1.2787th of 108 · median 0.69
HAE and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
HAE Haemonetics Corp$1.4B -2.0%59.6%7.5%11.6%21.6%1.27
LIVN LivaNova PLC$1.5B +10.7%67.8%13.0%14.3%8.6%0.22
ADUS Addus HomeCare Corp$1.5B +23.2%32.3%7.4%9.4%9.6%0.02
MDGL Madrigal Pharmaceuticals, Inc.$1.4B +432%--10.9%-24.8%-11.8%0.54
PGNY Progyny, Inc.$1.3B +10.4%24.9%6.8%22.0%13.4%-
GH Guardant Health, Inc.$1.3B +32.9%65.2%-37.9%--18.2%-
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by segment

From $993.2M of sales to $43.4M of profit FY2022

Revenue to Gross profit: $505.5MRevenue to Cost of revenue: $487.7MGross profit to Operating profit: $80.8MGross profit to Operating expenses: $424.8MOperating profit to Net profit: $43.4MOperating profit to Tax & other: $37.4MOperating expenses to R&D: $46.8MOperating expenses to Sales, admin & other: $378.0M Revenue: $993.2M REVENUE $993.2M +14% Y/Y Gross profit: $505.5M · 51% margin GROSS PROFIT $505.5M 51% margin · +27% Y/Y Cost of revenue: $487.7M · 49% of revenue COST OF REVENUE $487.7M 49% of revenue Operating profit: $80.8M · 8% margin OPERATING PROFIT $80.8M 8% margin · −10% Y/Y Operating expenses: $424.8M · 43% of revenue OPERATING EXPENSES $424.8M 43% of revenue Net profit: $43.4M · 4% margin NET PROFIT $43.4M 4% margin · −45% Y/Y Tax & other: $37.4M · 4% of revenue TAX & OTHER $37.4M 4% of revenue R&D: $46.8M · 5% of revenue R&D $46.8M 5% of revenue Sales, admin & other: $378.0M · 38% of revenue SALES, ADMIN & OTHER $378.0M 38% of revenue

From $1.2B of sales to $115.4M of profit FY2023

Revenue to Gross profit: $615.1MRevenue to Cost of revenue: $553.6MGross profit to Operating profit: $156.0MGross profit to Operating expenses: $459.1MOperating profit to Net profit: $115.4MOperating profit to Tax & other: $40.6MOperating expenses to R&D: $50.1MOperating expenses to Sales, admin & other: $408.9M Revenue: $1.2B REVENUE $1.2B +18% Y/Y Gross profit: $615.1M · 53% margin GROSS PROFIT $615.1M 53% margin · +22% Y/Y Cost of revenue: $553.6M · 47% of revenue COST OF REVENUE $553.6M 47% of revenue Operating profit: $156.0M · 13% margin OPERATING PROFIT $156.0M 13% margin · +93% Y/Y Operating expenses: $459.1M · 39% of revenue OPERATING EXPENSES $459.1M 39% of revenue Net profit: $115.4M · 10% margin NET PROFIT $115.4M 10% margin · +166% Y/Y Tax & other: $40.6M · 3% of revenue TAX & OTHER $40.6M 3% of revenue R&D: $50.1M · 4% of revenue R&D $50.1M 4% of revenue Sales, admin & other: $408.9M · 35% of revenue SALES, ADMIN & OTHER $408.9M 35% of revenue

From $1.3B of sales to $117.6M of profit FY2024

Revenue to Gross profit: $691.5MRevenue to Cost of revenue: $617.5MGross profit to Operating profit: $164.9MGross profit to Operating expenses: $526.7MOperating profit to Net profit: $117.6MOperating profit to Tax & other: $47.3MOperating expenses to R&D: $54.4MOperating expenses to Sales, admin & other: $472.2M Revenue: $1.3B REVENUE $1.3B +12% Y/Y Gross profit: $691.5M · 53% margin GROSS PROFIT $691.5M 53% margin · +12% Y/Y Cost of revenue: $617.5M · 47% of revenue COST OF REVENUE $617.5M 47% of revenue Operating profit: $164.9M · 13% margin OPERATING PROFIT $164.9M 13% margin · +6% Y/Y Operating expenses: $526.7M · 40% of revenue OPERATING EXPENSES $526.7M 40% of revenue Net profit: $117.6M · 9% margin NET PROFIT $117.6M 9% margin · +2% Y/Y Tax & other: $47.3M · 4% of revenue TAX & OTHER $47.3M 4% of revenue R&D: $54.4M · 4% of revenue R&D $54.4M 4% of revenue Sales, admin & other: $472.2M · 36% of revenue SALES, ADMIN & OTHER $472.2M 36% of revenue

From $1.4B of sales to $167.7M of profit FY2025

  • Hospital $564.3M
  • Plasma $535.4M
  • Blood Center $261.1M
Revenue to Gross profit: $749.0MRevenue to Cost of revenue: $611.9MGross profit to Operating profit: $221.8MGross profit to Operating expenses: $527.1MOperating profit to Net profit: $167.7MOperating profit to Tax & other: $54.1MOperating expenses to R&D: $62.7MOperating expenses to Sales, admin & other: $464.4M Revenue: $1.4B REVENUE $1.4B +4% Y/Y Gross profit: $749.0M · 55% margin GROSS PROFIT $749.0M 55% margin · +8% Y/Y Cost of revenue: $611.9M · 45% of revenue COST OF REVENUE $611.9M 45% of revenue Operating profit: $221.8M · 16% margin OPERATING PROFIT $221.8M 16% margin · +35% Y/Y Operating expenses: $527.1M · 39% of revenue OPERATING EXPENSES $527.1M 39% of revenue Net profit: $167.7M · 12% margin NET PROFIT $167.7M 12% margin · +43% Y/Y Tax & other: $54.1M · 4% of revenue TAX & OTHER $54.1M 4% of revenue R&D: $62.7M · 5% of revenue R&D $62.7M 5% of revenue Sales, admin & other: $464.4M · 34% of revenue SALES, ADMIN & OTHER $464.4M 34% of revenue

From $1.3B of sales to $97.3M of profit FY2026

  • Hospital $588.3M
  • Plasma $524.5M
  • Blood Center $221.3M
Revenue to Gross profit: $787.6MRevenue to Cost of revenue: $546.4MGross profit to Operating profit: $156.7MGross profit to Operating expenses: $630.9MOperating profit to Net profit: $97.3MOperating profit to Tax & other: $59.4MOperating expenses to R&D: $59.8MOperating expenses to Sales, admin & other: $571.1M Revenue: $1.3B REVENUE $1.3B −2% Y/Y Gross profit: $787.6M · 59% margin GROSS PROFIT $787.6M 59% margin · +5% Y/Y Cost of revenue: $546.4M · 41% of revenue COST OF REVENUE $546.4M 41% of revenue Operating profit: $156.7M · 12% margin OPERATING PROFIT $156.7M 12% margin · −29% Y/Y Operating expenses: $630.9M · 47% of revenue OPERATING EXPENSES $630.9M 47% of revenue Net profit: $97.3M · 7% margin NET PROFIT $97.3M 7% margin · −42% Y/Y Tax & other: $59.4M · 4% of revenue TAX & OTHER $59.4M 4% of revenue R&D: $59.8M · 4% of revenue R&D $59.8M 4% of revenue Sales, admin & other: $571.1M · 43% of revenue SALES, ADMIN & OTHER $571.1M 43% of revenue

Where each $100 of sales went

FY2022
FY2023
FY2024
FY2025
FY2026
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2026 against FY2021 · 10-K XBRL, year-end balances

Return on equity 12.2% FY2021: 10.9% net income ÷ equity
Net margin 7.3% FY2021: 9.1% profit per $ of sales: 97.3M ÷ 1.3B
Asset turnover 0.56× FY2021: 0.48× sales per $ of assets: 1.3B ÷ 2.4B
Leverage 3.01× FY2021: 2.49× assets per $ of equity: 2.4B ÷ 796.3M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    7.5% vs 6.8%
  • Gross margin up over 5 years
    45.7% → 59.0%
  • Return on equity below 15%
    11.6%
  • A profit in 9 of 10 years
Net margin, FY2017 to FY2026: -3.0% to 7.3%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 8.1× interest expense
  • Debt larger than equity
    Debt / equity 1.27 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 2.84
  • Net debt under 3 years of free cash flow
    $875.9M net debt, 2.9 years
Debt / equity at each year end, FY2017 to FY2026: 0.43 to 1.56

Cash and shareholders

  • Free cash flow positive in every one of 10 years
    $260.4M last year
  • Share count down over 5 years
    −7.7%
  • Cash from operations above net income
    $293.2M vs $97.3M
Free cash flow, FY2017 to FY2026: 83.6M to 260.4M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$1.1B of principal due, schedule of Sep 26, 2026

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Remaining performance obligations

Signed, not yet recognized $30.1M revenue under contracts the company has not delivered yet, Sep 26, 2026 · -15.2% on a year earlier

Contract liabilities

Paid in advance $67.3M cash received before delivery, not yet recognized as revenue, Sep 26, 2026 · +39.3% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

HAE's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue1.3B
FY2017: 886.1MFY2018: 903.9MFY2019: 967.6MFY2020: 988.5MFY2021: 870.5MFY2022: 993.2MFY2023: 1.2BFY2024: 1.3BFY2025: 1.4BFY2026: 1.3B FY2018FY2020FY2022FY2024FY2026
Net income97.3M
FY2017: -26.3MFY2018: 45.6MFY2019: 55.0MFY2020: 76.5MFY2021: 79.5MFY2022: 43.4MFY2023: 115.4MFY2024: 117.6MFY2025: 167.7MFY2026: 97.3M FY2018FY2020FY2022FY2024FY2026
Free cash flow260.4M
FY2017: 83.6MFY2018: 145.6MFY2019: 40.3MFY2020: 109.5MFY2021: 71.8MFY2022: 75.8MFY2023: 81.7MFY2024: 143.6MFY2025: 142.4MFY2026: 260.4M FY2018FY2020FY2022FY2024FY2026
Free cash flow after stock pay226.6M
FY2017: 74.5MFY2018: 132.5MFY2019: 23.1MFY2020: 89.0MFY2021: 46.2MFY2022: 51.4MFY2023: 56.1MFY2024: 115.3MFY2025: 112.8MFY2026: 226.6M FY2018FY2020FY2022FY2024FY2026
EPS (diluted)2.05
FY2017: -0.51FY2018: 0.85FY2019: 1.04FY2020: 1.48FY2021: 1.55FY2022: 0.84FY2023: 2.24FY2024: 2.29FY2025: 3.31FY2026: 2.05 FY2018FY2020FY2022FY2024FY2026
Diluted shares47.4M
FY2017: 51.5MFY2018: 53.5MFY2019: 52.9MFY2020: 51.8MFY2021: 51.3MFY2022: 51.4MFY2023: 51.4MFY2024: 51.4MFY2025: 50.7MFY2026: 47.4M FY2018FY2020FY2022FY2024FY2026

Revenue by business segment

year to Mar 28, 2026
RevenueSharevs year before
Hospital 588.3M44.1% +4.3%
Plasma 524.5M39.3% -2.0%
Blood Center 221.3M16.6% -15.3%

10-K 0000313143-26-000050, segment and revenue notes (XBRL).

Revenue by product or service

year to Mar 28, 2026
RevenueSharevs year before
Hospital 588.3M44.1% +4.3%
Blood Center 221.3M16.6% -15.3%

10-K 0000313143-26-000050, segment and revenue notes (XBRL).

Revenue by region

year to Mar 28, 2026
RevenueSharevs year before
United States 982.2M73.6% -2.8%
Europe 185.0M13.9% +5.3%
Rest of Asia 87.2M6.5% -5.5%
Japan 68.2M5.1% +9.3%
Other 11.4M0.9% -41.5%

10-K 0000313143-26-000050, segment and revenue notes (XBRL).

Revenue by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2022FY2023FY2024FY2025FY2026
Hospital-381.7M456.3M564.3M588.3M
Plasma-499.9M569.5M535.4M524.5M
Blood Center-287.0M283.2M261.1M221.3M
Business Unit972.7M1.1B1.3B--

Operating income by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2022FY2023FY2024FY2025FY2026
Plasma183.1M124.7M182.0M184.5M184.8M
Hospital129.8M29.4M52.2M89.0M103.7M
Blood Center136.7M64.3M42.4M52.8M50.0M
Corporate and other-156.0M164.9M221.8M156.7M

Revenue and operating income by business segment, as each 10-K reports them in its segment note (XBRL). Each year comes from the newest 10-K that reports it, so a year the company later recast shows the recast number; click a number to open that 10-K. Segments changed: FY2022, FY2023, FY2024 are in italics, as first reported under the earlier segments, so they are not comparable with the later years. Rows without a number were not reported as a separate segment that year. "Corporate and other" and "All other" are the 10-K's own lines for what is outside the segments.

Income statement

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue886.1M903.9M967.6M988.5M870.5M993.2M1.2B1.3B1.4B1.3B
Cost of revenue507.6M492.0M550.0M504.0M472.6M487.7M553.6M617.5M611.9M546.4M
Gross profit378.5M411.9M417.5M484.5M397.8M505.5M615.1M691.5M749.0M787.6M
R&D37.6M39.2M35.7M30.9M32.9M46.8M50.1M54.4M62.7M59.8M
SG&A301.7M316.5M273.5M282.0M275.2M340.1M376.7M429.8M436.8M442.4M
Operating income-19.4M56.2M83.5M103.4M89.7M80.8M156.0M164.9M221.8M156.7M
Interest expense7.8M7.7M12.6M13.5M9.4M5.8M13.0M19.5M35.9M19.3M
Pretax income-27.5M59.6M73.6M87.2M72.9M63.6M141.4M151.9M212.1M128.0M
Income tax-1.2M14.1M18.6M10.6M-6.6M20.3M26.0M34.3M44.4M30.7M
Net income-26.3M45.6M55.0M76.5M79.5M43.4M115.4M117.6M167.7M97.3M
EPS (diluted)-0.510.851.041.481.550.842.242.293.312.05
Diluted shares51.5M53.5M52.9M51.8M51.3M51.4M51.4M51.4M50.7M47.4M
Depreciation & amortization89.7M89.2M109.4M110.3M84.3M97.7M93.3M97.2M115.6M111.7M
EBITDA70.4M145.4M193.0M213.6M174.0M178.5M249.3M262.1M337.4M268.5M
Gross margin42.7%45.6%43.2%49.0%45.7%50.9%52.6%52.8%55.0%59.0%
Operating margin-2.2%6.2%8.6%10.5%10.3%8.1%13.4%12.6%16.3%11.7%
Net margin-3.0%5.0%5.7%7.7%9.1%4.4%9.9%9.0%12.3%7.3%
Revenue growth-+2.0%+7.0%+2.2%-11.9%+14.1%+17.7%+12.0%+4.0%-2.0%
EPS growth--+22.4%+42.3%+4.7%-45.8%+167%+2.2%+44.5%-38.1%

Cash flow

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow159.7M220.3M159.3M158.2M108.8M172.3M273.1M181.8M181.7M293.2M
Capital spending76.1M74.8M119.0M48.8M37.0M96.5M191.3M38.1M39.3M32.8M
Free cash flow83.6M145.6M40.3M109.5M71.8M75.8M81.7M143.6M142.4M260.4M
Stock-based pay (added back)9.2M13.0M17.2M20.5M25.5M24.4M25.6M28.3M29.6M33.8M
Free cash flow after stock pay74.5M132.5M23.1M89.0M46.2M51.4M56.1M115.3M112.8M226.6M
Buybacks0100.0M160.0M175.0M0075.0M0225.0M175.0M
Acquisitions----434.8M2.5M2.9M243.9M150.9M60.2M
Debt raised00347.8M0------
Debt repaid42.7M61.7M266.9M13.1M21.9M17.5M9.6M12.2M4.7M-
Investing cash flow-73.3M-63.0M-116.1M-57.2M-425.4M-86.3M-143.8M-322.4M-161.9M-179.5M
Financing cash flow-60.4M-120.6M-50.6M-131.2M367.5M-15.7M-100.4M38.2M108.8M-178.5M

Stock-based pay and leases

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Stock-based pay (expense)9.2M13.0M17.2M20.5M25.5M24.4M25.6M28.3M29.6M33.8M
Stock-based pay / revenue1.0%1.4%1.8%2.1%2.9%2.5%2.2%2.2%2.2%2.5%
Operating lease cost---8.3M11.7M11.0M11.0M10.6M12.1M10.4M
Operating lease cash paid---6.8M10.5M11.0M11.4M10.6M11.2M11.8M
Right-of-use assets---52.2M59.9M52.7M53.4M55.3M47.5M39.6M
Operating lease liabilities---59.3M70.7M62.9M63.1M66.1M58.6M50.1M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HAE/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.